Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Acta Derm Venereol. 2010 Mar;90(2):122-30. doi: 10.2340/00015555-0806.
There are substantial difficulties involved in carrying out clinical studies of recurrent herpes labialis, since the disease has a rapid onset, short-lasting viral shedding period and is rapidly self-healing. The aim of this paper was to critically assess published reports of episodic treatment of herpes labialis and to review biological and methodological problems involved in such studies. Limited, but statistically significant, results have been shown with topical antivirals, such as acyclovir and penciclovir, improving healing times by approximately 10%. Orally administrated antivirals, such as valaciclovir and famciclovir, have subsequently found clinical use. However, these two oral medications have different profiles in phase 3 studies. Famciclovir showed additional improvement of efficacy in terms of lesion healing time, but no effect on prevention of ulcerative lesions, while valaciclovir appeared to have similar efficacy to that of acyclovir cream on lesion healing, but some additional efficacy with respect to prevention of ulcerative lesions. A formulation of acyclovir/hydrocortisone showed further improvement in prevention of ulcerative lesions, while retaining efficacy with respect to lesion healing.
复发性唇疱疹的临床研究存在很大困难,因为该病发病迅速,病毒脱落期短,且具有自限性。本文旨在对复发性唇疱疹的偶发性治疗进行文献评价,并对这类研究中涉及的生物学和方法学问题进行综述。研究结果表明,局部应用抗病毒药物(如阿昔洛韦和喷昔洛韦)可有限地(但统计学上有显著意义)缩短愈合时间约 10%。随后发现口服抗病毒药物(如伐昔洛韦和泛昔洛韦)在临床上具有应用价值。然而,这两种口服药物在 3 期研究中的特征不同。泛昔洛韦在减少溃疡形成方面显示出额外的疗效改善,但对预防溃疡性病变无影响,而伐昔洛韦在减少溃疡形成方面似乎与阿昔洛韦乳膏的疗效相似,但对预防溃疡性病变有一定的额外疗效。阿昔洛韦/氢化可的松制剂在预防溃疡性病变方面进一步改善,同时保留对病变愈合的疗效。